Navigation Links
Vion Pharmaceuticals Receives a Standard Review from the FDA for Its New Drug Application for Onrigin(TM)
Date:4/23/2009

NEW HAVEN, Conn., April 23 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (OTC Bulletin Board: VION) today announced that the New Drug Application (NDA) for its lead oncology therapeutic Onrigin(TM) (laromustine) Injection has received a standard review classification by the U.S. Food and Drug Administration (FDA). Therefore, a user fee goal date of December 12, 2009 for a decision by the FDA with respect to the approval of the Company's NDA has been established.

The Company had previously announced the acceptance of the NDA filing for review by the FDA on April 16, 2009. The NDA presents data for Onrigin(TM) as a single agent for remission induction treatment for patients sixty years of age or older with de novo poor-risk acute myeloid leukemia (AML). The NDA is based on the results of an international multi-center pivotal Phase II trial of 85 patients sixty years of age or older with de novo poor-risk AML, supplemented by data from 55 patients in a previous Phase II trial in elderly AML. Eighty-six percent of these 140 patients had two or more risk factors that predicted for a poor prognosis.

Alan Kessman, Chief Executive Officer, commented, "Our level of excitement continues to grow as we move forward in the FDA's process of reviewing our NDA. We will continue to work closely with the FDA on the filing with the objective of achieving approval for Onrigin(TM) in its first indication in the United States." He added, "The positive news today is that we can expect to have an FDA decision this year."

About Vion Pharmaceuticals

Vion Pharmaceuticals, Inc. is committed to extending the lives and improving the quality of life of cancer patients worldwide by developing and commercializing innovative oncology therapeutics. Vion has two agents in clinical trials, Onrigin(TM)(laromustine) Injection and Triapine(R). The FDA is reviewing a New Drug Applicat
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Valeant Pharmaceuticals to Announce 2009 First Quarter Results on May 5, 2009
2. Genesis Pharmaceuticals Changes its Name to Jiangbo Pharmaceuticals, Inc. to Reflect its Brand Name
3. Lotus Pharmaceuticals, Inc. Reports Strong 2008 Financial Results
4. Genesis Pharmaceuticals Announces the Launch of Three TCM Products
5. Celator(R) Pharmaceuticals Presents New Data on CPX-351 And CPX-1 at the American Association for Cancer Research
6. Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Oral Picoplatin Demonstrating Bioavailability
7. Par Pharmaceutical Enters Into Agreement With Reliant Pharmaceuticals to Settle Patent Litigation Over Rythmol(R) SR
8. AUDIO from Medialink and Forest Pharmaceuticals: FDA Approves Lexapro for Major Depressive Disorder in Adolescents
9. Strativa Pharmaceuticals Provides Product Pipeline Update
10. ISTA Pharmaceuticals Announces Conference Call and Webcast of First Quarter 2009 Financial Results
11. Amylin Pharmaceuticals Reports First Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... Coordinating care for people with ... providers have not been reimbursed or rewarded for ... Medicare has paved the way by offering reimbursement ... launch of Oculus Health , an innovative ... the platform will now be able to easily ...
(Date:5/22/2015)... May 22, 2015 According to a new ... generations are equally as likely to worry about what will ... Gen X, 77% Boomers, 69% Silent Generation), which may help ... are scared of aging, particularly Millennials (47%), Gen X’ers (51%), ... Poll in April, 2015 among more than 2,000 U.S. adults ...
(Date:5/22/2015)... 22, 2015 Coco Libre, the Official Coconut ... World Record at the 104th running of the race. On ... luge served 315 people in one hour—one person about every ... is so true to the heart of the Bay Area, ... ice luge to the finish line only made sense,” said ...
(Date:5/22/2015)... PA (PRWEB) May 22, 2015 According to ... a hub for drug related death, totaling almost 2,500 confirmed ... as reported by state officials, totals 2,489 deaths stemming from ... work out, Pennsylvania loses seven people every day to fatal ... has been singled out as one of the most rife ...
(Date:5/22/2015)... Gateway Building Concepts is experienced with all ... company specialize in include decks, additions, kitchen remodeling, interior ... much more. , The redesigned logo is a ... company. It includes two geometrical lines that represent the ... to be used with many things associated with the ...
Breaking Medicine News(10 mins):Health News:Oculus Health Care Coordination Platform Officially Launched 2Health News:Oculus Health Care Coordination Platform Officially Launched 3Health News:Oculus Health Care Coordination Platform Officially Launched 4Health News:New Study Reveals America’s Fear of Aging 2Health News:New Study Reveals America’s Fear of Aging 3Health News:Coco Libre Ice Luge Sets New World Record at Bay to Breakers 2Health News:Philadelphia Ranks Among the Tops Cities in Penn. for Drug Deaths 2
... sure what spurs need for early treatment , TUESDAY, ... higher levels of education or disability typically need treatment ... study finds. , The study included 413 patients with ... trials of experimental drugs. The patients were assessed at ...
... , TROIS-RIVIERES, Quebec, July 14 ... beautiful and vibrant cities in all of Canada, and ... is recognized worldwide and has an international reputation for ... the growing drug problems facing Vancouver,s downtown eastside. "Our ...
... compliance, study finds , TUESDAY, July 14 (HealthDay News) -- ... use of a reminder program for women who were due ... Permanente staff checked electronic health records of its 35,000 members ... a mammogram for 20 months. They were sent a postcard ...
... , NEW YORK, July 14 NBC Universal communications ... of Senior Vice President, Communications, NBC Universal Women and Lifestyle Entertainment ... Communications. The announcement was made today by Lauren Zalaznick, President of ... report. , , For the last ...
... ARDEE, Ireland, July 14 Warner Chilcott Limited (Nasdaq: ... financial results prior to the market opening on Friday, August 7, 2009. ... a press release, the Company will host a conference call for all ... to review the results. To participate in the call, please dial (888) ...
... study finds , TUESDAY, July 14 (HealthDay News) -- People ... for heart disease, a U.S. study has found. , The ... home. At physical examinations conducted in 2005 and 2006, the ... in minutes and miles, and the percentage of the journey ...
Cached Medicine News:Health News:Educated Parkinson's Patients Move to Meds Sooner 2Health News:Crime, Drugs and Health Problems Face Vancouver's Downtown Eastside 2Health News:Reminders Boost Mammography Appointments 2Health News:Hilary Smith Upped to Senior Vice President, Communications, NBC Universal Women & Lifestyle Entertainment Networks 2Health News:Walking, Biking to Work Pays Off 2
(Date:5/22/2015)... , May 22, 2015   InspireMD, Inc. ... stent embolic protection systems ("EPS"), today announced that its CGuard ... lead by principle investigator Prof. Piotr Musialek , at ... Paris, France . PARADIGM, an ... R cutaneous c A roti D revascularization I ...
(Date:5/22/2015)... Today, Rhodes Pharmaceuticals L.P. announced that Aptensio ... for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) will ... The announcement comes just one month ... Food and Drug Administration (FDA). ... capsule with an onset of effect of 1 ...
(Date:5/22/2015)... , May 22, 2015 ... phase clinical research unit with a worldwide reputation ... for its frequent publications in peer reviewed medical ... European stakeholders and regulators in discussions about rules ...      (Logo: http://photos.prnewswire.com/prnh/20150522/745125) , ...
Breaking Medicine Technology:InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 2InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 3InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 4Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 2Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 3Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 4Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 5Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 6
... 2011  FUJIFILM Medical Systems U.S.A., Inc. today announced ... to the company,s Synapse® RIS and Synapse® TeleRIS ... (RSNA) 2011 Annual Meeting. Version 6.1 includes graphical ... to better monitor and manage performance in real ...
... Fovia Medical, Inc., a global leader in ... leading provider of healthcare enterprise imaging and information ... enhance its product offering by incorporating Fovia,s High ... zero-download v|Series product lines, including both web-accessible and ...
Cached Medicine Technology:Latest Version of Fujifilm's Synapse® RIS and TeleRIS Now Available 2Latest Version of Fujifilm's Synapse® RIS and TeleRIS Now Available 3DR Systems Embeds HDVR® in Unity RIS/PACS and Zero-Download v|Series 2DR Systems Embeds HDVR® in Unity RIS/PACS and Zero-Download v|Series 3
This a new dedicated VICTOR2 model for fluorescence and luminescence detection with stacker and robotic loading....
... This is the ... with the high density ... loading options. The extra ... minimizes the excitation beam ...
This is the modular manually operated VICTOR2 multilabel counter, with the addition of a xenon flash lamp for time-resolved fluorescence counting. Along with this option comes flash absorbance and du...
Flexible and sensitive fluorescence/luminescence microplate reader for endpoint and kinetic...
Medicine Products: